Investors appear unconcerned with AbbVie's (ABBV) late-stage failure with PARP inhibitor veliparib, as are analysts. Shares are up a fraction in early trading.
Bloomberg Intelligence's Cinney Zhang: Veliparib's worst-in-class potency has "minimal" implications for other PARPs from AstraZeneca (AZN +0.5%), TESARO (TSRO -3.5%) and Clovis Oncology (CLVS +2.1%).
SunTrust's Peter Lawson: No read-through for TSRO's Zejula (niraparib) in triple-negative breast cancer or lung cancer combo with Merck's Keytruda (pembrolizumab). Expects positive data on Zejula at ASCO in June.
Raymond James' Chris Raymond: Veliparib accounted for "minimal" of ABBV's sum-of-the-parts valuation ($2). Catalysts are Phase 3 data for ABT-494 in arthritis, venetoclax in CLL and Rova-T in lung cancer.
BMO's Alex Arfaei: Study miss was not a surprise, but it is "incrementally negative" for sentiment around ABBV's pipeline considering the increasing Humira competition.